Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate Neoadjuvant Gemcitabine Combined With Trastuzumab Rezetecan in HER2-positive Upper Tract Urothelial Carcinoma

NCT07741448 is registered in ClinicalTrials.gov with Zhiquan Hu as lead sponsor.

NCT NCT07741448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07741448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate Neoadjuvant Gemcitabine Combined With Trastuzumab Rezetecan in HER2-positive Upper Tract Urothelial Carcinoma
Lead sponsor
Zhiquan Hu
Phase
Phase 2
Overall status
Recruiting
Start date
August 15, 2026
Completion date
August 15, 2029
Enrollment
54 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

utuc